Daniela J. Hernández-Castillo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Daniela J. Hernández-Castillo has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Dora María Frias Márquez
Universidad Juárez Autónoma de Tabasco
1 shared publication - Erick de la Cruz-Hernandez
Universidad Juárez Autónoma de Tabasco
1 shared publication - Lucy Gloag
School of Chemistry , The University of New South Wales , Sydney , New South Wales 2052 , Australia
1 shared publication - Mayra Angélica Alvarez Lemus
Nanotechnology Laboratory-CICTAT, Academic Division of Engineering and Architecture, Juarez Autonomous University of Tabasco, Cunduacan, Tabasco, Mexico
1 shared publication - Patricia Quintana-Owen
Centro de Investigación y de Estudios Avanzados del IPN, Unidad Mérida, Mérida, México
1 shared publication - Richard David Tilley
School of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia
1 shared publication
Latest Publications
- Open Access
Albendazole Release from Silica-Chitosan Nanospheres. In Vitro Study on Cervix Cancer Cell Lines
In this work, a pH-responsive drug-carrier based on chitosan-silica nanospheres was developed as a carrier for Albendazole (ABZ), a poorly water-soluble anthelmintic drug. Spherical silica nanoparticles were obtained by Stöber method and further etched to obtain mesoporous particles with sizes ranging from 350 to 400 nm. The specific BET area of nanoparticles increased from 15 m2/g to 150 m2/g for etched silica, which also exhibited a uniform pore size distribution. X-ray powder diffraction showed the presence of amorphous phase of silica and a low-intensity peak attributed to ABZ for the drug-loaded nanoparticles. A uniform layer of chitosan was obtained ranging from 10 to 15 nm in thickness due to the small concentration of chitosan used (0.45 mg of chitosan/mg of SiO2). The in vitro evaluation of hybrid nanoparticles was performed using four cervical cancer cell lines CaSki, HeLa, SiHa and C33A, showing a significant reduction in cell proliferation (>85%) after 72 h. Therefore, we confirmed the encapsulation and bioavailability of the drug, which was released in a controlled way, and the presence of chitosan delayed the release, which could be of interest for the development of prolonged release drug delivery systems.
Open AccessAlbendazole Release from Silica-Chitosan Nanospheres. In Vitro Study on Cervix Cancer Cell Lines
In this work, a pH-responsive drug-carrier based on chitosan-silica nanospheres was developed as a carrier for Albendazole (ABZ), a poorly water-soluble anthelmintic drug. Spherical silica nanoparticles were obtained by Stöber method and further etched to obtain mesoporous particles with sizes ranging from 350 to 400 nm. The specific BET area of nanoparticles increased from 15 m2/g to 150 m2/g for etched silica, which also exhibited a uniform pore size distribution. X-ray powder diffraction showed the presence of amorphous phase of silica and a low-intensity peak attributed to ABZ for the drug-loaded nanoparticles. A uniform layer of chitosan was obtained ranging from 10 to 15 nm in thickness due to the small concentration of chitosan used (0.45 mg of chitosan/mg of SiO2). The in vitro evaluation of hybrid nanoparticles was performed using four cervical cancer cell lines CaSki, HeLa, SiHa and C33A, showing a significant reduction in cell proliferation (>85%) after 72 h. Therefore, we confirmed the encapsulation and bioavailability of the drug, which was released in a controlled way, and the presence of chitosan delayed the release, which could be of interest for the development of prolonged release drug delivery systems.